摘要
目的 探讨伊立替康联合顺铂对ⅠB-ⅡB期宫颈癌患者血管内皮生长因子表达的影响.方法 选取2014年 3月-2016年1月在我院治疗的ⅠB-ⅡB期宫颈癌患者 84例,采用随机数字表法平均分为对照组和观察组.对照组给予放疗和顺铂化疗,观察组在对照组治疗的基础上,给予伊立替康治疗.观察比较两组患者治疗血管内皮生长因子的水平以及表达情况.结果 治疗前后对照组和观察组患者的血管内皮生长因子的水平及表达均有-定程度的下降,但观察组患者的下降程度高于对照组,两者差异具有统计学意义（P〈0.05）.结论 伊立替康联合顺铂能够降低ⅠB-ⅡB 期宫颈癌患者的血管内皮生长因子的水平与表达,血管内皮生长因子可以作为宫颈癌预后的-个有价值的检测指标.
objective to investigate the correlation between the Iraq made for kang combined cisplatin Ⅰ B - Ⅱ B stage cervical cancer patients with the effect of vascular endothelial growth factor expression. Methods select in March 2014 - January 2016 in our hospital treatment Ⅰ B - Ⅱ B period, 84 cases of cervical cancer patients, using the random number table method divided into control group and observation group. The control group given and cisplatin chemotherapy, radiotherapy, on the basis of observation group was treated in the control group, giving the stand for the treatment. Compare two groups of patients treatment level and the expression of vascular endothelial growth factor. The results before and after treatment in the control group and observation group of patients with vascular endothelial growth factor levels and express all have a certain degree of decline, but the degree of decline in observation group of patients is higher than the control group, the difference statistically significant （P 〈 0.05）. Conclusion the stand for kang combined cisplatin can reduce Ⅰ B - Ⅱ B stage cervical cancer patients with vascular endothelial growth factor levels and expression, vascular endothelial growth factor can be used as the prognosis of cervical cancer a valuable detection index.
出处
《湖南中医药大学学报》
CAS
2016年第A01期329-330,共2页
Journal of Hunan University of Chinese Medicine
关键词
伊立替康
顺铂
ⅠB-ⅡB期宫颈癌
血管内皮生长因子
the stand for kang
Cisplatin. Ⅰ B - Ⅱ B stage cervical cancer
Vascular endothelial growth factor
